Friday, 21 October 2016

Diabetic Macular Edema Global Market Segmentation and Major Players Analysis 2022

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.


Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
- The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Diabetic Macular Edema Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Macular Edema - Overview 10
Pipeline Products for Diabetic Macular Edema - Comparative Analysis 11
Diabetic Macular Edema - Therapeutics under Development by Companies 12
Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes 16
Diabetic Macular Edema - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Diabetic Macular Edema - Products under Development by Companies 21
Diabetic Macular Edema - Products under Investigation by Universities/Institutes 24
Diabetic Macular Edema - Companies Involved in Therapeutics Development 25
Aciont Inc. 25
ActiveSite Pharmaceuticals, Inc. 26
Adverum Biotechnologies, Inc. 27
Aerpio Therapeutics, Inc. 28
Allergan Plc 29
Ampio Pharmaceuticals, Inc. 30
Araim Pharmaceuticals, Inc. 31
Astellas Pharma Inc. 32

Access Report @ https://www.wiseguyreports.com/reports/619281-diabetic-macular-edema-pipeline-review-h2-2016                                             

Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment